Categories: HealthcareNews

Turning Rock Partners Announces Successful Exit of MedShift

NEW YORK, Oct. 18, 2024 /PRNewswire/ — Turning Rock Partners (“TRP” or “Turning Rock”), a private investment firm based in New York, announced the realization of its $45 million investment in MedShift (the “Company”). The Company is a founder owned and led medical technology software provider based in Charlotte, NC. Turning Rock’s structured loan to the Company was fully realized through a full payoff of its obligations as the Company shifts to long term capital for growth.

TRP announced the realization of its $45 million investment in MedShift.

“Turning Rock is pleased to announce that MedShift has accomplished a new round of institutional debt financing that will drive its growth for the future,” said Turning Rock Senior Managing Director Erin Andrew. “We were pleased to partner with the Company on its expanding equipment and technology investments. Its next phase of growth will be driven by its exceptional management team. Our model of providing transitional capital to growing founder led companies was demonstrated here.”

Turning Rock Partners targets debt, equity and hybrid investments in underserved or capital constrained lower-middle market businesses in North America. TRP structures bespoke financing solutions for companies across the private market landscape.

“We thank Turning Rock for its support which enabled us to expand our investments in technology and team to realize strong growth,” said MedShift CEO Joe Gasque.

Turning Rock’s structured loan to the Company was contributed in April of 2023 as part of a broader $108M financing round led by management and existing shareholders.

About Turning Rock Partners:
Turning Rock Partners (TRP) targets debt, equity and hybrid investments in underserved or capital constrained lower-middle market businesses in North America. TRP structures bespoke financing solutions for companies across the private market landscape. For more information, please visit Turning Rock Partners’ website: www.turningrockpartners.com. For Turning Rock investor relations, please contact investor@turningrockpartners.com.

About MedShift:

Founded in 2015 and headquartered in Charlotte, NC, MedShift leads the healthcare sector with innovative SaaS solutions aimed at transforming medical manufacturing. At the core of MedShift’s success is its robust Software offerings, designed to empower the industry with cutting-edge tools for operational efficiency and growth. Through platforms like Velocity, a comprehensive SaaS solution, and Pulse IoT, a connected device ecosystem, MedShift leverages data and technology to enhance business performance and streamline workflows.

Media Contact:
Kate Shepherd, Kate@KateShepherdCommunications.com

View original content:https://www.prnewswire.com/news-releases/turning-rock-partners-announces-successful-exit-of-medshift-302280821.html

SOURCE Turning Rock Partners

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

51 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

52 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

55 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

55 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

55 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

55 minutes ago